« Previous article
IDEXX Water Test Sup...

16th February 2021  Content supplied by: Sona Nanotech Inc.

Sona Nanotech Receives CE-Mark for its Rapid COVID-19 Antigen Test

Sona Nanotech Inc. has been granted CE Mark status for its rapid COVID-19 antigen test. The CE mark declares the conformity of the Sona test with EU regulations and allows Sona to commercialize its test throughout Europe and potentially other territories in which the CE Mark is recognized.

The company intends to begin selling its test as a screening tool for organizations wishing to screen individuals in high-risk congregate settings in which testing could quickly identify persons with a SARS-CoV-2 infection to inform infection prevention and control measures to reduce risk of transmission. 

With its CE Mark secured, the company is now able to take firm orders in territories accepting a CE Mark and make corresponding manufacturing commitments from its contract manufacturer in the United Kingdom. 

Sona Nanotech is currently also in the process of technology transfer to a second manufacturer, in North America.  The Company will report quarterly on sales volumes and will update the market as material developments occur.

Sona’s rapid antigen test provides results in 15 minutes and is an immunochromatographic assay for the qualitative detection of the spike protein antigen from SARS-CoV-2 in nasopharyngeal (NP) swab specimens from individuals who are suspected of COVID-19. The assay is intended for professional use.

Sona continues to work with several potential partners to secure an additional clinical trial to support other potential regulatory submissions.  Any trial would require a sponsoring institution, a principal investigator, a study protocol, relevant medical ethics review board approval and Health Canada Investigational Testing Division approval. 

In advance of any such additional clinical trial, the Company continues to optimize its saliva-based prototype of its rapid, COVID-19 antigen test.

Sona recommends that users consult the CDC Interim Guidance for Antigen Testing for SARS-CoV-2



Date Published: 16th February 2021

Source article link: View

View full company details